Table of Content


List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Calcitonin Gene Related Peptide Type 1 Receptor (Calcitonin Receptor Like Receptor or CALCRL) - Overview
Calcitonin Gene Related Peptide Type 1 Receptor (Calcitonin Receptor Like Receptor or CALCRL) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Calcitonin Gene Related Peptide Type 1 Receptor (Calcitonin Receptor Like Receptor or CALCRL) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Calcitonin Gene Related Peptide Type 1 Receptor (Calcitonin Receptor Like Receptor or CALCRL) - Companies Involved in Therapeutics Development
AbbVie Inc
Adepthera LLC
Amgen Inc
Biohaven Pharmaceutical Holding Company Ltd
Modulus Oncology Ltd
Shanghai Junshi Bioscience Co Ltd
Calcitonin Gene Related Peptide Type 1 Receptor (Calcitonin Receptor Like Receptor or CALCRL) - Drug Profiles
atogepant - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
erenumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
HTL-0022562 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
JS-010 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
rimegepant sulfate ODT - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SHF-1036 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Target CALCRL and RAMP for Resistant Hypertension - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
zavegepant hydrochloride - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Calcitonin Gene Related Peptide Type 1 Receptor (Calcitonin Receptor Like Receptor or CALCRL) - Dormant Products
Calcitonin Gene Related Peptide Type 1 Receptor (Calcitonin Receptor Like Receptor or CALCRL) - Discontinued Products
Calcitonin Gene Related Peptide Type 1 Receptor (Calcitonin Receptor Like Receptor or CALCRL) - Product Development Milestones
Featured News & Press Releases
Jun 23, 2021: Sosei Heptares initiates phase 1 trial with novel small-molecule CGRP antagonist under collaboration with Biohaven
Jun 23, 2021: Amgen announces approval Of Aimovig (frenumab) in Japan for the suppression of onset of migraine attacks in adults
Jun 03, 2021: Biohaven announces presentations on Zavegepant at the 2021 virtual annual scientific meeting of the American Headache Society
Jun 03, 2021: Biohaven showcases CGRP-antagonist franchise data including Nurtec ODT (rimegepant), now approved to treat and prevent migraine attacks, and presentations at the 2021 virtual annual scientific meeting of the American Headache Society
May 27, 2021: FDA approves Biohaven’s Nurtec ODT (Rimegepant) for prevention: now the first and only migraine medication for both acute and preventive treatment
May 14, 2021: Biohaven’s Nurtec ODT signs as primary partner with Rick Ware Racing for 2021 NTT INDYCAR Series Program
Apr 13, 2021: Biohaven announces presentations on Zavegepant at the 2021 American Academy of Neurology (AAN) Virtual Annual Meeting
Apr 13, 2021: Biohaven announces presentations on rimegepant at the 2021 American Academy of Neurology (AAN) Virtual Annual Meeting
Apr 07, 2021: AbbVie to present data on Atogepant at the 2021 American Academy of Neurology (AAN) Annual Meeting
Mar 30, 2021: U.S. FDA accepts AbbVie’s New Drug Application for Atogepant for the preventive treatment of Migraine
Mar 30, 2021: Biohaven initiates enrolment in migraine treatment trial
Mar 11, 2021: Biohaven’s nurtec ODT approved in United Arab Emirates for acute treatment of migraine
Mar 10, 2021: Biohaven’s Nurtec ODT approved in Israel for acute treatment of migraine
Jan 25, 2021: Biohaven announces prelimiry 4Q2020 net product revenue for NURTEC ODT
Jan 18, 2021: Biohaven signs Cody Ware as driver for Nurtec ODT Chevrolet for the 2021 SCAR Cup series season
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer



List of Figures

List of Figures
Number of Products under Development by Stage of Development, 2021
Number of Products under Development by Therapy Areas, 2021
Number of Products under Development by Top 10 Indications, 2021
Number of Products by Mechanism of Actions, 2021
Number of Products by Stage and Mechanism of Actions, 2021
Number of Products by Routes of Administration, 2021
Number of Products by Stage and Routes of Administration, 2021
Number of Products by Molecule Types, 2021
Number of Products by Stage and Molecule Types, 2021

List of Tables

List of Tables
Number of Products under Development by Stage of Development, 2021
Number of Products under Development by Therapy Areas, 2021
Number of Products under Development by Indication, 2021
Number of Products under Development by Companies, 2021
Products under Development by Companies, 2021
Products under Development by Companies, 2021 (Contd..1)
Number of Products by Stage and Mechanism of Actions, 2021
Number of Products by Stage and Route of Administration, 2021
Number of Products by Stage and Molecule Type, 2021
Pipeline by AbbVie Inc, 2021
Pipeline by Adepthera LLC, 2021
Pipeline by Amgen Inc, 2021
Pipeline by Biohaven Pharmaceutical Holding Company Ltd, 2021
Pipeline by Modulus Oncology Ltd, 2021
Pipeline by Shanghai Junshi Bioscience Co Ltd, 2021
Dormant Products, 2021
Dormant Products, 2021 (Contd..1)
Discontinued Products, 2021